- Center on Health Equity & Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
Success in Value-Based Contracting—Using Evidence, Technology, and Data to Improve Outcomes and Eliminate Low-Value Care, Part 3
Experts from Optum, WellMed, and Reliant discuss strategies for bringing value-based payment into specialty care through the use of education and analytics.
In the latest Matters in Managed Care webinar, experts discussed how to improve outcomes and eliminate low-value care. They defined actions and practices that constitute wasted and harmful care, described how to rapidly translate high-quality evidence-based medicine into daily practice, recognized how to leverage technology, and more.
Ken Cohen, MD, FACP, senior medical director and executive director, clinical research national senior medicaldirector, Optum Care, moderated the panel with:
- Troy Comstock, MD, regional medical director, Florida WellMed Medical Management
- Dan Murrey, MD, MPP, chief medical officer, surgical care associates; president, OptumCare Specialty Practices
- Thad Schilling, MD, chief medical officer, Reliant Medical Group
In segment 3, they discussed using analytics to control drug spend and optimize care.
Varied Access: The Pharmacogenetic Testing Coverage Divide
February 18th 2025On this episode of Managed Care Cast, we speak with the author of a study published in the February 2025 issue of The American Journal of Managed Care® to uncover significant differences in coverage decisions for pharmacogenetic tests across major US health insurers.
Listen
Neurologists Share Tips for Securing Patient Access to Gene Therapies
March 19th 2025Tenacious efforts at every level, from the individual clinician to the hospital to the state to Congress, will be needed to make sure patients can access life-saving gene therapies for neuromuscular diseases.
Read More
How Access to SMA Treatment Varies Globally and by Insurance Type
March 18th 2025Posters presented at the 2025 Muscular Dystrophy Association (MDA) Clinical & Scientific Conference show that therapeutic advances in treating spinal muscular atrophy (SMA) are not uniformly making it into the hands of patients who could benefit.
Read More
